Rationale for adjunctive therapies targeting inflammation pathobiology based phenotypes in pediatric sepsis; from Meningococcemia/atypical Hemolytic Uremic Syndrome, to H1N1 Influenza/Methicillin Resistant Staphylococcus Aureus, to Critical Pertussis, to Epstein Barr Virus Lymphoproliferative Diseas